Business Context and Reporting Period
This filing is a Form 10-Q for Histogenics Corporation, not Ocugen, Inc., for the quarter and nine months ended September 30, 2015. Histogenics was a clinical-stage regenerative medicine company developing NeoCart, an investigational cartilage-repair product in a 245-patient Phase 3 trial under an FDA Special Protocol Assessment. Enrollment was expected to be completed in the second quarter of 2017. The filing states that NeoCart had not been approved for sale and that the company had no approved products.
Financial Metrics
| Metric | Three Months Ended September 30, 2015 | Nine Months Ended September 30, 2015 | Comparable Prior Period |
|---|---|---|---|
| Revenue | No material operating revenue reported | No material operating revenue reported | No clear comparable revenue value provided |
| Research and development expense | $5.8 million | $17.5 million | $13.2 million and $21.3 million, respectively |
| General and administrative expense | $2.2 million | $6.0 million | $1.7 million and $4.8 million, respectively |
| Net loss | $8.1 million | $23.7 million | $12.0 million and $23.7 million, respectively |
| Loss per share | $0.61 | $1.79 | $19.38 and $45.49, respectively |
| Net cash used in operating activities | Not provided | $23.0 million | $13.3 million |
| Cash and cash equivalents | $37.7 million at September 30, 2015 | $58.1 million at December 31, 2014 |
The company had no meaningful commercial revenue base and no meaningful gross margin or operating margin to report. Accumulated deficit was $157.2 million at September 30, 2015. Total assets were $45.3 million, total liabilities were $9.1 million, and stockholders’ equity was $36.2 million.
Debt consisted primarily of an equipment loan. Outstanding borrowings were approximately $1.49 million at September 30, 2015, including $583,000 classified as current and $907,000 as long-term. The company stated that it was in compliance with applicable loan covenants.
Material Changes Versus the Prior Comparable Period
- Third-quarter research and development expense declined 56% to $5.8 million, primarily because the 2014 period included a $10.0 million non-cash charge for licensed technology acquired under the Intrexon collaboration. The decline was partly offset by higher quality and regulatory consulting costs, clinical enrollment costs, facility costs, personnel costs, and stock-based compensation.
- Nine-month research and development expense decreased 18% to $17.5 million, while general and administrative expense increased 25% to $6.0 million due primarily to higher directors’ and officers’ insurance, board-related costs, depreciation, stock-based compensation, and recruiting expense.
- Third-quarter net loss improved from $12.0 million to $8.1 million, but the comparison benefited from the absence of a $3.0 million fair-value gain recorded in the 2014 period on warrant and other liabilities.
- Operating cash usage increased 74% to $23.0 million for the nine months, and cash declined $20.3 million from year-end 2014. Financing cash inflows were $4.5 million, including $4.7 million from the IPO overallotment.
- Shares outstanding increased to 13.27 million at September 30, 2015 from 12.76 million at December 31, 2014, primarily reflecting the IPO overallotment and option exercises.
Outlook, Risks, Contingencies, and Unusual Items
- Management expected existing cash to fund projected needs into 2017 but stated that substantial additional capital would be required for continued clinical development, manufacturing capacity, regulatory activities, and commercialization. Additional financing might be unavailable or dilutive.
- The company expected continuing net losses and increasing expenses for at least the next several years and did not expect significant product revenue unless NeoCart or another product candidate obtained regulatory approval and was commercialized.
- A key near-term risk was the transition of NeoCart raw-material manufacturing from external suppliers to company-controlled or directed facilities. The company stated that available raw materials were expected to support the Phase 3 trial through the end of the first quarter of 2016, requiring completion of the technology transfer by then.
- The FDA could require additional comparability evidence, preclinical work, or clinical trials for the transferred materials, potentially delaying enrollment, regulatory approval, or commercialization.
- In September 2015, the company entered into a three-year collagen supply agreement requiring a non-refundable payment of $121,000 by year-end 2015 and annual minimum purchases of $150,000 beginning after the first 12 months.
- Other commitments included a $190,000 remaining payment for a multi-unit bioreactor system, potential license milestone payments, annual minimum royalties, and future product royalties.
- The company disclosed no material pending legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of September 30, 2015.
- Material risks included clinical-trial failure or enrollment delays, FDA non-approval, manufacturing and supply interruptions, intellectual-property challenges, dependence on third parties and key personnel, competition, reimbursement uncertainty, future dilution, and potential inability to continue funding operations.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is for Histogenics Corporation, whereas the request metadata identifies Ocugen, Inc.
- Verify the status, enrollment progress, and subsequent results of the NeoCart Phase 3 trial and whether the stated 2017 enrollment target was achieved.
- Assess cash runway against actual operating cash burn and determine when additional financing was ultimately required.
- Review whether the FDA accepted the transferred NeoCart raw materials as comparable and whether manufacturing or regulatory issues caused delays.
- Check subsequent equity, debt, collaboration, or licensing transactions and the resulting dilution or changes in control.
- Evaluate the status of NeoCart, the Intrexon collaboration, the collagen supply agreement, and related milestone or royalty obligations.